Regeneron Pharmaceuticals reported first-in-human data for its investigational CIDEBsiRNA in MASLD, with a single subcutaneous dose showing dose-dependent liver fat reductions of 58% to 80% at week 36...
Source LinkRegeneron Pharmaceuticals reported first-in-human data for its investigational CIDEBsiRNA in MASLD, with a single subcutaneous dose showing dose-dependent liver fat reductions of 58% to 80% at week 36...
Source Link
Comments